27 July 2020 | News
Brinton has received approval from DCGI to market Favipiravir anti-viral tablets in India.
Image Credit: shutterstock.com
Pune based Brinton Pharmaceuticals, one of the leading pharmaceutical companies in India has recently received approval from Drugs Controller General of India (DCGI) to market Favipiravir under the brand name Faviton. It will be available in 200mg tablets. Brinton is one of the top few companies to market this drug in India and it will also be exporting Faviton globally.
Emerging favorable global clinical evidence suggests, Favipiravir is an effective treatment option in the management of mild to moderate COVID 19. As this is an orally administered medication, it is more convenient compared to intravenously administered medicines. In India, Favipiravir was first approved by the regulatory authorities in June’20 under emergency use authorization to treat COVID 19 patients.
Mr. RahulKumar Darda, CMD commented, “As a socially responsible company, we always wanted to launch an “evidence-based cure” to combat COVID 19. Our strategic intent will be to improve the access through our strong distribution network that will help make Faviton available across all COVID treatment centers and our MRP is Rs.59 per tab”.
Faviton will be available in a strip of 10 tablets and 50 tablets in a box, which is a rational pack for the treatment. Faviton is indicated in the treatment of patients with mild to moderate COVID-19 disease and comes with 90 days shelf-life.